Wall Street analysts predict that Curis, Inc. (NASDAQ:CRIS) will announce sales of $2.03 million for the current quarter, according to Zacks. Two analysts have made estimates for Curis’ earnings, with estimates ranging from $1.90 million to $2.15 million. Curis reported sales of $2.36 million during the same quarter last year, which would suggest a negative year over year growth rate of 14%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Curis will report full year sales of $2.03 million for the current fiscal year, with estimates ranging from $8.50 million to $8.79 million. For the next year, analysts forecast that the company will report sales of $9.69 million per share, with estimates ranging from $8.97 million to $10.40 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Curis.

Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.21) EPS.

A number of research firms have recently issued reports on CRIS. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Zacks Investment Research upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Finally, Guggenheim began coverage on shares of Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.50.

In related news, CEO Ali Ph.D. Fattaey purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the completion of the purchase, the chief executive officer now owns 115,890 shares in the company, valued at $122,843.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.07% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. boosted its holdings in Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 1,880 shares during the period. Rhumbline Advisers boosted its holdings in shares of Curis by 1.9% during the second quarter. Rhumbline Advisers now owns 127,529 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 2,340 shares during the period. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Curis by 9.3% during the first quarter. Metropolitan Life Insurance Co. NY now owns 90,156 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 7,638 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Curis by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 8,102 shares during the period. Finally, Voya Investment Management LLC raised its stake in shares of Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 12,207 shares in the last quarter. Institutional investors and hedge funds own 55.22% of the company’s stock.

Curis (NASDAQ CRIS) traded up $0.02 on Thursday, hitting $0.84. 2,105,690 shares of the stock were exchanged, compared to its average volume of 777,623. Curis has a 12 month low of $0.78 and a 12 month high of $3.48. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.

COPYRIGHT VIOLATION NOTICE: “Curis, Inc. (CRIS) Expected to Announce Quarterly Sales of $2.03 Million” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/07/curis-inc-cris-expected-to-announce-quarterly-sales-of-2-03-million-2.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.